These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27035983)

  • 1. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors.
    Krampitz GW; George BM; Willingham SB; Volkmer JP; Weiskopf K; Jahchan N; Newman AM; Sahoo D; Zemek AJ; Yanovsky RL; Nguyen JK; Schnorr PJ; Mazur PK; Sage J; Longacre TA; Visser BC; Poultsides GA; Norton JA; Weissman IL
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4464-9. PubMed ID: 27035983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
    Michaels AD; Newhook TE; Adair SJ; Morioka S; Goudreau BJ; Nagdas S; Mullen MG; Persily JB; Bullock TNJ; Slingluff CL; Ravichandran KS; Parsons JT; Bauer TW
    Clin Cancer Res; 2018 Mar; 24(6):1415-1425. PubMed ID: 29288236
    [No Abstract]   [Full Text] [Related]  

  • 3. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
    Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
    Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
    Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
    Young K; Lawlor RT; Ragulan C; Patil Y; Mafficini A; Bersani S; Antonello D; Mansfield D; Cingarlini S; Landoni L; Pea A; Luchini C; Piredda L; Kannan N; Nyamundanda G; Morganstein D; Chau I; Wiedenmann B; Milella M; Melcher A; Cunningham D; Starling N; Scarpa A; Sadanandam A
    Gut; 2021 Oct; 70(10):1904-1913. PubMed ID: 32883872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal.
    Liu M; O'Connor RS; Trefely S; Graham K; Snyder NW; Beatty GL
    Nat Immunol; 2019 Jan; 20(3):265-275. PubMed ID: 30664738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
    Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E
    J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors.
    Hunter KE; Palermo C; Kester JC; Simpson K; Li JP; Tang LH; Klimstra DS; Vlodavsky I; Joyce JA
    Oncogene; 2014 Apr; 33(14):1799-808. PubMed ID: 23644656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.
    Baccelli I; Stenzinger A; Vogel V; Pfitzner BM; Klein C; Wallwiener M; Scharpff M; Saini M; Holland-Letz T; Sinn HP; Schneeweiss A; Denkert C; Weichert W; Trumpp A
    Oncotarget; 2014 Sep; 5(18):8147-60. PubMed ID: 25230070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
    Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
    Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
    Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
    [No Abstract]   [Full Text] [Related]  

  • 18. p53 and p16
    Azzopardi S; Pang S; Klimstra DS; Du YN
    Neoplasia; 2016 Oct; 18(10):610-617. PubMed ID: 27664376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
    Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
    Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
    Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
    Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.